BALTIMORE, May 7, 2019 /PRNewswire/ -- Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization (CDMO) who recently entered into a definitive agreement with Catalent, Inc., announced today the appointment of John R. Mosack as the Vice President of Manufacturing for its clinical through commercial-scale gene therapy facility in Baltimore, Maryland. Additionally, Paragon has appointed Adam Sachs as the Vice President of Program Management and Strategic Client Alliance to further support its customers throughout the life cycle of their product.
"These two new positions allow Paragon to create a true environment of excellence in manufacturing," said Pete Buzy, Paragon's President and CEO. "John's extensive experience with high-quality GMP production facilities will be a great asset to the Paragon team. Additionally, Adam's focus on client deliverables and timelines will provide our customers with the support and attention needed for the future success of their products."
John joins Paragon with over 25 years of GMP operations management, validation and compliance experience in small- and large-scale clinical and commercial biologics manufacturing operations. Most recently, he was the Site Head for Lonza's Bioscience and Cell Therapy operations at the Walkersville, Maryland production facility. Prior to that, John spent 5 years as the Site General Manager of Bristol-Myers Squibb's Syracuse, New York facility where he oversaw biologics manufacturing for clinical and commercial drug substance. John has played key roles in leading organizational readiness for successful commercial licensure of several biologics. Beyond the operational management experience, John spent nine years at KMI/PAREXEL managing validation and compliance projects in the biologics, pharmaceutical and medical device industries. John holds a bachelor's degree in Mechanical Engineering from the University of Massachusetts, Amherst.
Adam comes to Paragon with over 25 years of experience in Program and Alliance Management, Operations/Supply Chain Management and Business Development within the biotech and pharma industries. Most recently he completed 10+ successful years at AstraZeneca/MedImmune where he served as Senior Director in both business development and alliance management. As the Alliance Director, Adam oversaw all commercial antibody supply collaborations and played a critical lead role in the accelerated commercial launch of a blockbuster biologic oncology drug. Adam began his career at Life Technologies, where over a ten-year period he held several roles of increasing scope and responsibility, including Director of Manufacturing for both make-to-stock and just-in-time manufacturing operations. He has also held executive positions at two Maryland-based biotech companies. Adam holds a master's degree in Chemical Engineering from the University of California, San Diego, and a B.S. in Chemistry from the University of Michigan.
In addition to the two new leadership positions, Paragon recently promoted Deborah Wild to Chief Quality and Regulatory Affairs Officer. This move continues to secure and advance Paragon's commitment to producing high-quality product. Ms. Wild is an accomplished quality executive with more than 30 years of experience. Most recently, she ran a thriving consulting practice where she led quality assurance-focused initiatives for high-profile clients such as Genentech, TEVA, Polynoma, Cytovance and CMC Biologics. Managing her consulting on the side, Ms. Wild occupied full-time roles at Polynoma as VP of Quality Systems and VP of Manufacturing and Supply Chain at Victory Pharma. Prior to launching her practice, she spent more than 17 years at Genentech. Additionally, Ms. Wild served in the U.S. Army where she was deployed to Desert Storm toward the end of her enlistment. She began as a Private First Class and held the ranking of Staff Sergeant upon her departure from active service.
"Paragon, and soon-to-be Catalent, is committed to building a gene therapy manufacturing center of excellence for our customers," said Ruby Hofmann, Senior Vice President of Human Resources and Organizational Development. "Ms. Wild has a strong reputation for adding to company growth strategies by effectively transforming Quality organizations into strong business partners. It is this industry-leading experience that will form the backbone of our manufacturing programs."
Paragon recently announced plans to expand its operations on the BWI campus with a second GMP gene therapy production facility. The campus currently holds 200,000 square-feet of state-of-the-art GMP gene therapy biomanufacturing space that is equipped with 500L and 2000L single-use bioreactors for clinical trial and commercial material production.
Paragon Bioservices is an industry-leading, private-equity backed CDMO whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon aims to build strong client partnerships with the world's best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses) and other complex biologics. For more information, please visit www.paragonbioservices.com.
Press and Media Contact:
PH +1 443 261 3246
SOURCE Paragon Bioservices, Inc.